Harrisson S et al. Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444). (Abstract PS-111)
Vroege behandeling van milde tot matige COVID-19 met sotrovimab reduceert risico op progressie
apr 2022 | Pneumonie, Virale infecties